Results 191 to 200 of about 144,610 (311)

Residual disease after neoadjuvant therapy in HER2-positive breast cancer: biology, burden, or both? [PDF]

Transl Cancer Res
Di Lena É, Takabe K.
europepmc   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Futility of resection after neoadjuvant therapy in pancreatic ductal adenocarcinoma. [PDF]

iScience
Luo HT, Xie ZQ, Chen SJ, Yu QQ, Xu XY, Wu J, Teng TH.   +6 more
europepmc   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, EarlyView.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

Organ preservation with total neoadjuvant therapy in early-stage rectal cancer: A statewide analysis. [PDF]

Colorectal Dis
Bunjo Z, Fitzsimmons T, Nguyen TM, Penniment M, Selva-Nayagam S, Tonkin D, Sia TC, Murphy E, Thomas M, Sammour T.   +9 more
europepmc   +1 more source

Limb Compression Therapy and Chemotherapy‐Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self‐Controlled Study(NEURO‐GLOVE Trial)

International Journal of Cancer, EarlyView.
With no effective drug‐based prevention strategies available for chemotherapy‐induced peripheral neuropathy (CIPN), research in neuroprotective approaches has grown. Of particular interest is mechanical compression, which may protect nerves by temporarily reducing blood flow during treatment. The authors here conducted a prospective trial in women with
Kadriye Başkurt, Galip Can Uyar, Enes Yeşilbaş, Fatma Zehra Altunç, Damla Erimhan Çevik, İsmet Murat Melek, Yasemin Eren, Ömür Berna Çakmak Öksüzoğlu, Kadriye Bir Yücel, Antonio Di Meglio, Isabelle Ray‐Coquard, Osman Sütcüoğlu   +11 more
wiley   +1 more source

Development and verification of a prognostic nomogram model for triple-negative breast cancer patients with neoadjuvant therapy. [PDF]

Front Oncol
Zhang Y, Zhang X, Wang X, Zhang Y, Tang X, Zhang Z, Guo H.   +6 more
europepmc   +1 more source

α2,3‐Sialyltransferase (ST3Gal1) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF‐R2/JAK2/STAT3 signaling cascades

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods ST3Gal1 and
Wei‐Ting Chao, Chia‐Hao Liu, Szu‐Ting Yang, Chen‐Hao Lin, Liang‐Wei Wang, Peng‐Hui Wang   +5 more
wiley   +1 more source

Global hotspots and trends in the application of neoadjuvant therapy for gastric cancer: a bibliometric analysis. [PDF]

Front Oncol
Wang Z, Kong L, Jiang TY, Zhang Q, Chen L, Zhao J, Wang F.   +6 more
europepmc   +1 more source

The role of human microbiota in breast cancer pathogenesis and treatment

iMeta, EarlyView.
The human microbiota contributes to breast cancer pathogenesis and treatment response through interactions involving the oral, gut, and breast microbial niches. (Left) Multi‐site dysbiosis is characterized by altered microbial composition and abundance across different anatomical sites.
Jie Qiu, Xiaojia Wang, Man Li, Jing Guo, Shipeng Ning, Yi‐Zhou Gao, Xinyi Zhang, Xuli Meng, Yiding Chen, Yunxiang Zhou   +9 more
wiley   +1 more source